Shanghai Junshi Biosciences Co P/L
Qual é o P/L de Shanghai Junshi Biosciences Co?
O P/L de Shanghai Junshi Biosciences Co., Ltd. é N/A
Qual é a definição de P/L?
A razão entre preço e lucro é a razão entre o preço das ações de uma empresa e o lucro por ação da empresa, calculado ao longo de doze meses.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/L de empresas na Setor Health Care em OTC em comparação com Shanghai Junshi Biosciences Co
O que Shanghai Junshi Biosciences Co faz?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Empresas com p/l semelhantes a Shanghai Junshi Biosciences Co
- Skyfii tem P/L de N/A
- CareRx tem P/L de N/A
- Copper Search tem P/L de N/A
- Fayenceries de Sarreguemines, Digoin & Vitry-le-Francois Societe Anonyme tem P/L de N/A
- Universe Entertainment and Culture tem P/L de N/A
- Wenye tem P/L de N/A
- Shanghai Junshi Biosciences Co tem P/L de N/A
- TeraGo tem P/L de N/A
- Poly Culture tem P/L de N/A
- Turnium Technology Inc tem P/L de N/A
- Embracer AB (publ) tem P/L de N/A
- Shun Ho Property Investments tem P/L de N/A
- Domo tem P/L de N/A